Base Year
Historical Year
Forecast Year
The value of the global scleroderma therapeutics market was USD 2.04 billion in 2023, driven by increasing prevalence of scleroderma, rising awareness about the disease across the globe. The market is expected to grow at a CAGR of 6.20% during the forecast period of 2024-2032 to reach value of USD 3.50 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Scleroderma refers to an autoimmune condition that affects the skin, vessels of the blood, muscles, and internal organs. Usually, the disease is caused by an abnormal immune response. Immunosuppressive medicines and, in some cases, glucocorticoids are included to treat this condition.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The drug class available in the industry can be divided into:
Based on indication, the scleroderma therapeutics market can be divided into:
The EMR report looks into the regional markets of scleroderma therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The demand in the industry is mainly being driven by the use of off-label medications approved. The lack of curative drugs and a higher prevalence of off-label drug use are the underlying factors that drive interest in markets for rare diseases. The advancement of targeted biologics, as well as small molecular combination therapies, are expected to be supported in the industry. The market is also projected to be supported by the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment. The rising disposable incomes, allowing greater expenditure, and the existence of a well-defined regulatory framework that promotes successful therapy production in developed regions are driving the growth of the industry.
The report presents a detailed analysis of the following key players in the global scleroderma therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the scleroderma therapeutics market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Indication |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
In 2023, the global scleroderma therapeutics market attained a value of nearly USD 2.04 billion.
The market is projected to grow at a CAGR of 6.20% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 3.50 billion by 2032.
The major industry drivers include rising population, advancement of targeted biologics, and small molecular combination therapies and the use of off-label medications approved.
The key industry trends driving growth include the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant drug classes available are immunosuppressors, phosphodiesterase 5 inhibitors – PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers and analgesics, among others.
The leading indication types of the industry are systemic and localized.
The major players in the industry are F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, arGentis™ Pharmaceuticals, LLS, Kadmon Holdings, Inc., Emerald Health, Pharmaceuticals Inc., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share